TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis,
Teva's President and CEO, will present at the 43(rd) Annual J.P. Morgan
Healthcare Conference on Monday, January 13, 2025. The presentation will begin
at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).
To access a live webcast of the presentation, visit Teva's Investor Relations
website at https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the
end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global
pharmaceutical leader, harnessing our generics expertise and stepping up
innovation to continue the momentum behind the discovery, delivery, and expanded
development of modern medicine. For over 120 years, Teva's commitment to
bettering health has never wavered. Today, the company's global network of
capabilities enables its -37,000 employees across 58 markets to push the
boundaries of scientific innovation and deliver quality medicines to help
improve health outcomes of millions of patients every day. To learn more about
how Teva is all in for better health, visit www.tevapharm.com
(http://www.tevapharm.com).
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management's current beliefs and expectations and are
subject to substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to differ
significantly from that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such differences include
risks relating to: our ability to successfully compete in the marketplace
including our ability to successfully execute our Pivot to Growth strategy,
including to expand our innovative and biosimilar medicines pipeline and
profitably commercialize the innovative medicines and biosimilar portfolio,
whether organically or through business development, and to sustain and focus
our portfolio of generics medicines; our substantial indebtedness; our business
and operations in general including the impact of global economic conditions and
other macroeconomic developments and the governmental and societal responses
thereto; compliance, regulatory and litigation matters; other financial and
economic risks; and other factors discussed in our Quarterly Report on Form 10-Q
for the third quarter of 2024 and in our Annual Report on Form 10-K for the year
ended December 31, 2023, including in the sections captioned "Risk Factors."
Forward-looking statements speak only as of the date on which they are made, and
we assume no obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new information,
future events or otherwise. You are cautioned not to put undue reliance on these
forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
(mailto:TevaCommunicationsNorthAmerica@tevapharm.com)
Teva Investor Relations Inquires
TevaIR@Tevapharm.com (mailto:TevaIR@Tevapharm.com)
Â